These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32537431)

  • 21. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
    Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
    Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
    de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
    Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.
    Xu S; Ramos-Suzarte M; Bai X; Xu B
    Oncotarget; 2016 May; 7(22):33391-407. PubMed ID: 27050148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.
    Solomon MT; Miranda N; Jorrín E; Chon I; Marinello JJ; Alert J; Lorenzo-Luaces P; Crombet T
    Cancer Biol Ther; 2014 May; 15(5):504-9. PubMed ID: 24521695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab.
    Wu Q; Zhu C; Zhang S; Zhou Y; Zhong Y
    Front Oncol; 2021; 11():762366. PubMed ID: 34746003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
    Menon N; Patil V; Noronha V; Joshi A; Bhattacharjee A; Satam BJ; Mathrudev V; Ghosh Laskar S; Prabhash K
    Oral Oncol; 2021 Nov; 122():105517. PubMed ID: 34560383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India.
    Yadav A; Goyal P; Agrawal CR; Bothra SJ; Jain P; Choudhury KD; Gupta SK; Sharma M; Bajaj R; Upadhyay A; Dash P; Doval DC
    Indian J Cancer; 2020; 57(1):76-83. PubMed ID: 32129298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
    Zhao XY; Guo Y; Zhu YX; Wang Y; Zhu GP; Hu CS; Ji QH
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jul; 47(7):536-9. PubMed ID: 22932235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
    Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
    Huang J; Zou Q; Qian D; Zhou L; Yang B; Chu J; Pang Q; Wang K; Zhang F
    Onco Targets Ther; 2017; 10():5835-5841. PubMed ID: 29263680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
    Bhuvaneswari R; Ng QF; Thong PS; Soo KC
    Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence.
    Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
    South Asian J Cancer; 2018; 7(3):188-192. PubMed ID: 30112336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence.
    Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
    South Asian J Cancer; 2019; 8(2):112-115. PubMed ID: 31069192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
    Zhai RP; Ying HM; Kong FF; Du CR; Huang S; Zhou JJ; Hu CS
    Onco Targets Ther; 2015; 8():3383-90. PubMed ID: 26604795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.